9.07
+0.37(+4.25%)
Currency In USD
| Previous Close | 8.7 |
| Open | 8.22 |
| Day High | 9.38 |
| Day Low | 7.39 |
| 52-Week High | 30.1 |
| 52-Week Low | 5.2 |
| Volume | 263,324 |
| Average Volume | 100,654 |
| Market Cap | 79.86M |
| PE | -0.36 |
| EPS | -26 |
| Moving Average 50 Days | 9.25 |
| Moving Average 200 Days | 9.12 |
| Change | 0.68 |
If you invested $1000 in Sutro Biopharma, Inc. (STRO) since IPO date, it would be worth $59.67 as of December 04, 2025 at a share price of $9.07. Whereas If you bought $1000 worth of Sutro Biopharma, Inc. (STRO) shares 5 years ago, it would be worth $40.04 as of December 04, 2025 at a share price of $9.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format anti
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
GlobeNewswire Inc.
Nov 12, 2025 3:00 PM GMT
- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor webcast today at 7:00AM PT / 10:00AM ET - SOUT